Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARCT-810

Other · Protein replacement · developed by Arcturus Therapeutics

Phase 2 Most advanced trial

ARCT Developer

1 Registered trials

What is ARCT-810?

ARCT-810 is an investigational messenger RNA encoding ornithine transcarbamylase (OTC), formulated in a lipid nanoparticle. It is being studied in ornithine transcarbamylase deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Mechanism: Protein replacement
Therapy area: Neurology
Developer: Arcturus Therapeutics, Inc. (ARCT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06488313	Phase 2	OTC Deficiency	Recruiting	ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ornithine Transcarbamylase DeficiencyOTC DeficiencyOTCD

More from Arcturus Therapeutics

ARCT-021 Phase 2 ARCT-032 Phase 2 ARCT-154 Phase 2/3 ARCT-165 Phase 1/2 ARCT-2138 Phase 1 ARCT-2303 Phase 3 ARCT-2304 Phase 1/2

Sources

ClinicalTrials.gov NCT06488313

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.

Follow ARCT, the company behind ARCT-810

See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARCT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z